Seek Returns

DHR vs. INSM: Danaher vs. Insmed Stock Comparison

How do Danaher (DHR) and Insmed (INSM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and Insmed (INSM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while INSM is classified in Biotechnology.

Company profile comparison for Danaher (DHR) and Insmed (INSM)
Profile ItemDHRINSM
NameDanaher Corp.Insmed Incorporated
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization161.86 billion USD25.10 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateDecember 29, 1978June 1, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

DHR
INSM
GSPC
Loading price history…
Danaher (DHR) vs. Insmed (INSM), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Danaher (DHR) and Insmed (INSM). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Danaher (DHR) and Insmed (INSM). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
Total Return (1Y)11.88%-39.17%
Total Return (3Y, Annualized)6.67%70.17%
Total Return (5Y, Annualized)-2.05%28.96%

Risk Profile

Drawdown History

DHR
INSM
GSPC
Loading price history…
Danaher (DHR) vs. Insmed (INSM), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Danaher (DHR) and Insmed (INSM). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
Volatility (1Y, Annualized)30.61%63.09%
Beta (5Y)0.760.80
Max Drawdown (5Y)-43.31%-56.54%
Avg. Volume (3M)3.94M2.76M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
DHR and INSM are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
Sharpe Ratio (1Y)0.25-0.69
Sortino Ratio (1Y)0.35-1.04

Profitability

ROE (TTM)

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Danaher (DHR) reports 8.19%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max
109.18%
DHR
8.19%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-72.45%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
INSM
-72.45%
Min
-167.77%
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Danaher (DHR) reports 16.91%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max
18.05%
DHR
16.91%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.85%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
INSM
-39.85%
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Danaher (DHR) reports 21.13%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max
83.12%
DHR
21.13%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-15.60%

Max
83.12%
Q3
14.77%
Median
0.00%
INSM
-15.60%
Q1
-78.82%
Min
-207.40%
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
ROE (TTM)8.19%-72.45%
ROA (TTM)4.06%-17.25%
Net Margin (TTM)16.91%-39.85%
Operating Margin (TTM)21.13%-15.60%
Gross Margin (TTM)59.36%84.40%

Growth

Revenue Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Danaher (DHR) at 2.90% is closer to the peer norm — faster top-line expansion for INSM.

Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Danaher (DHR) reports EPS growth of -4.54%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
Revenue Growth (YoY)2.90%66.73%
Revenue Growth (3Y CAGR)-2.67%35.20%
EPS Growth (YoY)-4.54%--
EPS Growth (3Y CAGR)-19.44%--

Financial Strength

Current Ratio (MRQ)

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
DHR
1.63
Min
0.10

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

Max
25.13
Q3
12.13
Median
5.52
INSM
2.86
Q1
2.47
Min
0.10
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Danaher (DHR) at 0.52 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max
1.42
Q3
0.65
DHR
0.52
Median
0.15
Q1
0.02
Min
0.00

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max
1.42
INSM
1.01
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
Current Ratio (MRQ)1.632.86
Debt / Equity (MRQ)0.521.01
Net Debt / EBITDA2.68--

Dividends

Dividend Yield (TTM)

Insmed (INSM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR
0.67%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Insmed (INSM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR
25.17%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
Dividend Yield (TTM)0.67%0.00%
Dividend Payout Ratio (TTM)25.17%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Danaher (DHR) trades at 38.12 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max
85.34
Q3
43.46
DHR
38.12
Median
26.69
Q1
13.30
Min
0.07

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
INSM
--
Loading chart…
Danaher (DHR) vs. Insmed (INSM): INSM does not report P/E ratio, so it has no value marker; DHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Danaher (DHR) at 6.32 and Insmed (INSM) at 16.52 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max
58.18
Q3
25.77
Median
7.30
DHR
6.32
Q1
3.01
Min
0.01

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.52

Max
58.18
Q3
25.77
INSM
16.52
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Danaher (DHR) at 3.02 sits near its industry’s typical P/B ratio, while Insmed (INSM) at 34.55 prices above its benchmark range — INSM looks rich relative to book.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max
13.53
Q3
6.54
Median
3.25
DHR
3.02
Q1
1.69
Min
-5.59

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.55

INSM
34.55
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Danaher (DHR) vs. Insmed (INSM): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and Insmed (INSM)
MetricDHRINSM
P/E Ratio (TTM)38.12--
P/S Ratio (TTM)6.3216.52
P/B Ratio (MRQ)3.0234.55
Free Cash Flow Yield (TTM)2.93%-1.82%